Sponsored by Alkermes, Inc., Cambridge, MA, and Cephalon, Inc., and Frazer, PA.
Poster presented at the American Society of Addiction Medicine, April 11-13, 2008, Toronto
Studies with Extended-Release Naltrexone Charles O'Brien, MD, PhD1, David R. Gastfriend, MD2, Robert F. Forman, PhD2, Helen M. Pettinati, PhD1
1Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA; 2Alkermes, Inc., Cambridge MA
ABSTRACT Background: Monthly injection of extended-release naltrexone (XR-NTX) in conjunction with psychosocial support is an effective treatment for…